ICAM1 and hepatocellular carcinoma: The findings suggest that ICAM‐1 activates platelets and promotes endothelial permeability in TAECs through VE‐cadherin after insufficient RFA, and anti‐platelet and anti‐ICAM‐1 therapy can be used to prevent progression of HCC after insufficient RFA.